Skip to main content
ETST
OTC Life Sciences

ETST Q1 Revenue Reaches $9M, Net Income $716K; Buyback Continues, CEO Voting Control Revealed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Neutral
Importance info
7
Price
$0.093
Mkt Cap
$26.746M
52W Low
$0.001
52W High
$0.237
52W Position
Off High info
61% below high
Rel. Volume info
4.9× avg
Market data snapshot near publication time

ETST filed a Earnings and Guidance on elevated volume (4.9× avg).

Summary

Earth Science Tech reported Q1 FY2027 revenue of $9.03M and net income of $716K, repurchased 3.7M shares, and disclosed CEO voting control via Series B Preferred Stock.


Key Events · Earnings and Guidance · ETST

  • Q1 Revenue $9.03M, Net Income $716K

    Revenue increased 3% YoY to $9,025,779; net income available to common stockholders was $724,192, or $0.003 per share, compared to $465,039 a year ago.

  • Share Repurchase: 3.7M Shares Retired

    The company spent $392,191 to repurchase and retire 3,733,726 shares during the quarter, reducing outstanding shares to 287.6 million.

  • CEO Voting Control via Series B Preferred

    The CEO holds all outstanding Series B Preferred Stock, which carries 150% voting power relative to common stock, giving him voting control over all shareholder matters including the upcoming annual meeting.

  • No Dilutive Financing Since Early 2023

    Management reiterated its commitment to non-dilutive growth; no equity securities have been sold since early 2023, and authorized common shares were previously reduced from 750M to 300M.


Analysis · ETST · Life Sciences

Earth Science Tech delivered $9.03 million in quarterly revenue, a 3% year-over-year increase, alongside net income of $715,697. During the quarter, 3.7 million shares were repurchased and retired for $392,191, extending the company's non-dilutive capital allocation strategy. The filing also discloses that the CEO holds super-voting preferred stock conferring 150% voting power, which solidifies insider control ahead of the August 31 annual meeting where a controversial reverse split proposal is on the ballot. For a micro-cap name, the mix of steady operations, ongoing buybacks, and concentrated governance makes this a notable update.

At the time of this filing, ETST was trading at $0.09 on OTC in the Life Sciences sector, with a market capitalization of approximately $26.7M. The 52-week trading range was $0.00 to $0.24. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ETST - Latest Insights

ETST
Jul 02, 2026, 4:30 PM EDT
Filing Type: PRE 14A
Importance Score:
9
ETST
Jun 18, 2026, 6:15 AM EDT
Source: Wiseek News
Importance Score:
8
ETST
Jun 18, 2026, 6:06 AM EDT
Filing Type: 10-K
Importance Score:
7
ETST
Jun 10, 2026, 8:43 AM EDT
Source: Wiseek News
Importance Score:
8
ETST
Jun 10, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
8